Table 4.
Posttherapy Resistance Profiles of MBA Patients with Pretherapy Resistance Mutations
| Patient ID | Date | Timing | NRTI | NNRTI | Regimen |
|---|---|---|---|---|---|
| MBA1057 | 11/1/2005 | Pre-ARV | T69A/D/N/T | Y181C/Y | — |
| MBA1057 | 5/22/2006 | Post-ARV | Wildtype | Wildtype | 3TC/d4T/NVPa |
| MBA1057 | 11/22/2006 | Post-ARV | D067N, T069D, K070K/R, M184V, K219N | K103N, Y181C | 3TC/d4T/NVP |
| MBA1057 | 6/14/2007 | Post-ARV | D067N, T069D, K070R, M184V, K219N | K103N, Y181C | 3TC/AZT/NVP |
| MBA1057 | 9/6/2007 | Post-ARV | D067N, T069D, K070R, M184V, L210L/V, K219N | K103N, Y181C | 3TC/AZT/NVP |
| MBA1057 | 2/14/2008 | Post-ARV | D067N, T069D, K070R, M184V, K219N | K103N, Y181C | 3TC/AZT/NVP |
| MBA1118b | 8/10/2006 | Pre-ARV | Wildtype | K103K/N | — |
| MBA1118 | 1/10/2008 | Post-ARV | Wildtype | Wildtype | 3TC/d4T/NVPa |
| MBA1118 | 5/27/2009 | Post-ARV | M184V | K103N | Untreated |
| MBA1202 | 1/18/2007 | Pre-ARV | Wildtype | K103K/N, Y181C/Y | — |
| MBA1202 | 6/11/2007 | Post-ARV | M184V | K103K/N, Y181C | 3TC/d4T/NVPa |
| MBA1202 | 7/4/2007 | Post-ARV | M184V | K103K/N, Y181C | 3TC/d4T/NVP |
| MBA1202 | 12/13/2007 | Post-ARV | M184V | Y181C | 3TC/d4T/NVP |
| MBA1294 | 6/28/2007 | Pre-ARV | Wildtype | K103K/N/R/S | — |
| MBA1294 | 11/30/2009 | Post-ARV | Wildtype | K103N | 3TC/AZT/NVPa |
| MBA1294 | 3/17/2010 | Post-ARV | M184V | K103N, M230L | 3TC/AZT/NVP |
| MBA1300 | 7/13/2007 | Pre-ARV | Wildtype | K101E/K | — |
| MBA1300 | 10/15/2007 | Post-ARV | M184V | K101E | 3TC/AZT/NVPa |
| MBA1300 | 3/26/2008 | Post-ARV | M184V | K101E/K, G190A | 3TC/AZT/NVP |
| MBA1300 | 6/19/2008 | Post-ARV | M184V | G190A | 3TC/AZT/NVP |
| MBA1300 | 8/28/2008 | Post-ARV | M184V | G190A | 3TC/AZT/NVP |
| MBA1300 | 4/1/2009 | Post-ARV | M184V | G190A | 3TC/AZT/NVP |
| MBA1309b | 7/31/2007 | Pre-ARV | M184V | K103N | — |
| MBA1309 | 10/24/2007 | Post-ARV | M184V | K103N, E138E/Q | 3TCa/AZT/NVPa/LPV |
| MBA1309 | 1/15/2008 | Post-ARV | M184V | K103N, E138E/Q | 3TC/d4T/NVP/LPV |
| MBA1309 | 4/8/2008 | Post-ARV | M184V | K103N, E138Q | 3TC/d4T/NVP/LPV |
| MBA1450 | 9/11/2008 | Pre-ARV | Wildtype | K103N | — |
| MBA1450 | 2/3/2010 | Post-ARV | M184V | K103N | 3TC/AZT/NVPa |
| MBA1470b | 11/4/2008 | Pre-ARV | Wildtype | K103N | — |
| MBA1470 | 7/20/2009 | Post-ARV | K070K/R, M184V | K103N | 3TC/AZT/NVPa |
| MBA1470 | 1/6/2010 | Post-ARV | M184V, L210L/W, T215Y | K103N, M230L | 3TC/AZT/NVP |
a
Drugs in the initial ARV regimens that the patients might not have received if their pretherapy resistance profiles were known.
b
Patients who had detectable plasma drug concentration pretherapy (see Table 2).
All other patients developed additional drug resistance mutations over time. No PI-associated resistance mutations were detected.
Only MBA, not AMU, patients had follow-up resistance genotyping. MBA 1130 and 1306 were lost to follow-up. MBA 1161, 1323, 1347, 1466, and 1467 had no longitudinal sequences available.